TODAY'S MARKET INTELLIGENCE
CanSino's Tetanus Vaccine Approved by NMPA, Phase III Shows Superior Immunogenicity
English summary
CanSino Biologics announced that its adsorbed tetanus vaccine has been approved by China's NMPA for new drug listing, for non-neonatal tetanus prevention. Phase III data showed superior antibody GMC at 30 days post-vaccination versus control, and the company has reached an exclusive commercialization agreement with Yuanda Life Sciences. The approval may boost its vaccine commercialization.
The English text is machine translated and may require verification against the Chinese version.
Browse today's intelligence